PMID- 29996317
OWN - NLM
STAT- MEDLINE
DCOM- 20180731
LR  - 20181202
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 47
IP  - 7
DP  - 2018 Jul 8
TI  - [HER2 gene status and mRNA expression in immunohistochemistry 1+ breast cancer].
PG  - 522-526
LID - 10.3760/cma.j.issn.0529-5807.2018.07.008 [doi]
AB  - Objective: To investigate human epidermal growth factor 2 (HER2) gene status and 
      in situ mRNA expression in breast cancers with immunohistochemistry(IHC) 1+ , and 
      to reveal HER2 positive rate in these patients to provide reference data for 
      obtaining precise HER2 results and modifying relevant clinical strategy to breast 
      cancer. Methods: Sixty-five IHC 1+ formalin-fixed and paraffin-embedded samples 
      of invasive breast carcinoma of no special type (IBC-NST) were collected by 
      surgical operation at Peking Union Medical College Hospital during 2011 to 2013. 
      HER2 status and in situ mRNA expression were tested by fluorescence in situ 
      hybridization (FISH) and RNAscope, respectively, by using tissue microarray. 
      Metastatic lymph node was re-tested by FISH if HER2 status was equivocal or 
      negative and with high expression of mRNA in the primary lesion. Results: Four of 
      65 samples (6.2%) were FISH positive, which included 2 cases of HER2/CEP17>2 and 
      average HER2 copy number>4 and 2 cases of HER2/CEP17<2 and average HER2 copy 
      number>6. In the 4 samples of HER2 positive, 2 patients showed high in situ mRNA 
      expression (3 scores by RNAscope), 2 patients showed moderate in situ mRNA 
      expression (2 scores by RNAscope). In addition, 3 specimens with HER2/CEP17>2 and 
      average HER2 copy number<4 were found in all patients, which included 2 cases of 
      high in situ mRNA expression (3 and 4 scores by RNAscope) and 1 cases of moderate 
      in situ mRNA expression (2 scores by RNAscope). There was no significant 
      association between HER2 status or mRNA expression and clinicopathological 
      characteristics, including tumor size, histopathological differentiation, lymph 
      node metastasis and lymphovascular invasion (P>0.05). Conclusions: A small number 
      of HER2 IHC 1+ patients exist mRNA expression by using FISH method, which 
      suggested that these patients might benefit from anti-HER2 therapy potentially. 
      Since the importance for patients with breast cancers to develop diagnostic and 
      therapeutic strategies from accurate molecular typing, further studies based on a 
      larger cohort are needed to validate our findings.
FAU - Wu, S F
AU  - Wu SF
AD  - Molecular Pathology Research Center, Department of Pathology, Peking Union 
      Medical College Hospital, Chinese Academy of Medicine Sciences, Beijing 100730, 
      China.
FAU - Liu, Y Y
AU  - Liu YY
FAU - Liu, X D
AU  - Liu XD
FAU - Jiang, Y
AU  - Jiang Y
FAU - Luo, Y F
AU  - Luo YF
FAU - Cui, Q C
AU  - Cui QC
FAU - Liang, Z Y
AU  - Liang ZY
FAU - Zeng, X
AU  - Zeng X
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (RNA, Messenger)
RN  - 1HG84L3525 (Formaldehyde)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - Formaldehyde
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymph Nodes/metabolism
MH  - Lymphatic Metastasis
MH  - RNA, Messenger/metabolism
MH  - Receptor, ErbB-2
OTO - NOTNLM
OT  - Breast neoplasms
OT  - Genes, erbB-2
OT  - Immunohistochemistry
OT  - In situ hybridization
OT  - RNA, messenger
EDAT- 2018/07/13 06:00
MHDA- 2018/08/01 06:00
CRDT- 2018/07/12 06:00
PHST- 2018/07/12 06:00 [entrez]
PHST- 2018/07/13 06:00 [pubmed]
PHST- 2018/08/01 06:00 [medline]
AID - 10.3760/cma.j.issn.0529-5807.2018.07.008 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2018 Jul 8;47(7):522-526. doi: 
      10.3760/cma.j.issn.0529-5807.2018.07.008.